[HTML][HTML] Resistance to hypomethylating agents in myelodysplastic syndrome and acute myeloid leukemia from clinical data and molecular mechanism
G Zhao, Q Wang, S Li, X Wang - Frontiers in Oncology, 2021 - frontiersin.org
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.
G Zhao, Q Wang, S Li, X Wang - Frontiers in Oncology, 2021 - europepmc.org
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
G Zhao, Q Wang, S Li, X Wang - Frontiers in oncology, 2021 - pubmed.ncbi.nlm.nih.gov
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
[HTML][HTML] Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
G Zhao, Q Wang, S Li, X Wang - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been
developed as targeted therapies to reverse DNA methylation in different cancer types, and …
developed as targeted therapies to reverse DNA methylation in different cancer types, and …